Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) Invested Capital (2020 - 2025)

Historic Invested Capital for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to $1.2 million.

  • Ensysce Biosciences' Invested Capital fell 8258.07% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 8258.07%. This contributed to the annual value of $3.7 million for FY2024, which is 66941.65% up from last year.
  • Per Ensysce Biosciences' latest filing, its Invested Capital stood at $1.2 million for Q3 2025, which was down 8258.07% from $3.4 million recorded in Q2 2025.
  • Ensysce Biosciences' 5-year Invested Capital high stood at $6.9 million for Q3 2024, and its period low was -$8.2 million during Q4 2021.
  • For the 5-year period, Ensysce Biosciences' Invested Capital averaged around $554740.4, with its median value being $1.3 million (2022).
  • As far as peak fluctuations go, Ensysce Biosciences' Invested Capital crashed by 135915.43% in 2022, and later surged by 66941.65% in 2024.
  • Ensysce Biosciences' Invested Capital (Quarter) stood at -$8.2 million in 2021, then surged by 50.61% to -$4.0 million in 2022, then soared by 83.84% to -$651267.0 in 2023, then surged by 669.42% to $3.7 million in 2024, then tumbled by 67.55% to $1.2 million in 2025.
  • Its Invested Capital stands at $1.2 million for Q3 2025, versus $3.4 million for Q2 2025 and $3.0 million for Q1 2025.